MDM2 and colorectal carcinoma: In this study, after inhibition of the MAPK pathway by selumetinib (MEK1/2 inhibitor) and stabilization of p53 pathway by KRT-232 (MDM2 inhibitor), we observed significantly increased growth inhibitory activity both in vitro and in vivo in CRC and PTC with MAPK alterations and TP53 WT.